Background: Selenium (Se) is a micronutrient, which has recently been proven to have a positive effect on the immune system of cancer patients, but the underlying mechanism is not clearly defined. In this randomized controlled trial, we evaluated the effect of three-month Se supplementation on the profile of CD4(+) T-helper subsets including IFN-gamma(+)/IL-4(-) Th1, IFN-gamma(-)/IL-4(+) Th2, and CD4(+)IL-17(+) Th17 cells in sixteen diffuse large B cell lymphoma (DLBCL) patients at stable remission phase who consumed Se (Se+) compared to the fourteen control patients who did not receive Se (Se-). Methods: The frequency of IFN-gamma(+)/IL-4(-) Th1, IFN-gamma(-)/IL-4(+) Th2, and CD4(+)IL-17(+) Th17 lymphocytes was determined using a four-color flow cytometry method. Results: The results revealed that three-month Se supplementation significantly decreased the proportion of CD4(+)IL-17(+) Th17 lymphocytes but not IFN-gamma(+)/IL-4(-) Th1 and IFN-gamma(-)/IL-4(+) Th2 subtypes in DLBCL patients at stable remission. Change in the percentage of IFN-gamma(+)/IL-4(-) Th1, IFN-gamma(-)/IL-4(+) Th2, and CD4(+)IL-17(+) Th17 cells did not significantly differ between Se+ and Se- groups. No positive correlation was observed between changes in different Th subpopulations in both Se+ and Se- groups. Conclusions: Taken together, three-month Se supplementation can reduce the proportion of CD4(+)IL-17(+) Th17 cells in DLBCL patients at stable remission phase. Larger population and longer follow-up of patients is necessary to specify the clinical significance of Se supplementation on the popularity of T-helper cells in DLBCL patients.